Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have advanced non-small cell lung cancer with an EGFR mutation (except certain types like exon 20 insertions).
- Your cancer must have gotten worse while taking osimertinib, and your doctor thinks you can still take it.
- A tumor sample taken after osimertinib stopped working must show high or intermediate levels of a protein called c-MET.
- You need to have measurable disease on scans and be in good enough health to get around and take care of yourself (ECOG score 0-1).
- You cannot have had certain lung problems like pulmonary fibrosis or active inflammation of the lungs.
- You must have adequate kidney, liver, and blood cell counts, and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.